These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 25829373

  • 1. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C, Sojo-Dorado J, Barriga A, Lavín-Alconero L, Palacios Z, López-Hernández I, Merino V, Camean M, Pascual A, Rodríguez-Baño J, FOREST Study Group.
    BMJ Open; 2015 Mar 31; 5(3):e007363. PubMed ID: 25829373
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
    Yamamoto A, Yamasaki K.
    Nihon Ronen Igakkai Zasshi; 2015 Mar 31; 52(2):153-61. PubMed ID: 25994987
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K.
    Int Urol Nephrol; 2015 Jul 31; 47(7):1059-66. PubMed ID: 26026972
    [Abstract] [Full Text] [Related]

  • 4. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
    Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, Arda B, Ulusoy S.
    J Chemother; 2010 Oct 31; 22(5):355-7. PubMed ID: 21123160
    [Abstract] [Full Text] [Related]

  • 5. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K, Grey J, Fronczek C, Marr K.
    Am J Health Syst Pharm; 2020 Nov 16; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN, Samuelsen Ø, Jakobsen L, Småbrekke L, Andersson DI, Sundsfjord A, Frimodt-Møller N.
    Antimicrob Agents Chemother; 2018 Jun 16; 62(6):. PubMed ID: 29581117
    [Abstract] [Full Text] [Related]

  • 7. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P, Boroumand MA, Rahbar M, Douraghi M.
    Microb Drug Resist; 2018 Jun 16; 24(5):607-612. PubMed ID: 29064348
    [Abstract] [Full Text] [Related]

  • 8. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
    Ten Doesschate T, van Mens SP, van Nieuwkoop C, Geerlings SE, Hoepelman AIM, Bonten MJM.
    BMC Infect Dis; 2018 Dec 05; 18(1):626. PubMed ID: 30518334
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
    Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M, AIDA consortium.
    BMJ Open; 2016 Apr 20; 6(4):e009956. PubMed ID: 27098822
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W, Li B, Song J, Hong Y, Zhang X, Liu H, Lu H, Zhou T, Cao J.
    Int J Antimicrob Agents; 2017 Jul 20; 50(1):29-34. PubMed ID: 28456703
    [Abstract] [Full Text] [Related]

  • 12. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL.
    Trials; 2015 Jan 27; 16():24. PubMed ID: 25623485
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y, Inan-Erdogan I, Fukuchi K, Wakabayashi H, Ogawa Y, Hibino S, Sakurai S, Matsuhashi K, Watanabe Y, Hashimoto K, Ugajin K, Itabashi K.
    J Infect Chemother; 2017 Aug 27; 23(8):517-522. PubMed ID: 28528936
    [Abstract] [Full Text] [Related]

  • 14. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T, Ozyurt M, Baylan O, Bektöre B, Ardiç N, Ceylan S, Erdemoğlu A, Haznedaroğlu T.
    Mikrobiyol Bul; 2009 Oct 27; 43(4):645-9. PubMed ID: 20084918
    [Abstract] [Full Text] [Related]

  • 15. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT, May DB.
    Am J Ther; 2013 Oct 27; 20(6):685-90. PubMed ID: 21768870
    [Abstract] [Full Text] [Related]

  • 16. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo FJ, Campos J, Spanish ESBL-EARS-Net Study Group.
    J Antimicrob Chemother; 2010 Nov 27; 65(11):2459-63. PubMed ID: 20851815
    [Abstract] [Full Text] [Related]

  • 17. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.
    Arch Intern Med; 2008 Sep 22; 168(17):1897-902. PubMed ID: 18809817
    [Abstract] [Full Text] [Related]

  • 18. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL.
    Int J Antimicrob Agents; 2016 Jul 22; 48(1):56-60. PubMed ID: 27234673
    [Abstract] [Full Text] [Related]

  • 19. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
    Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, Jones N.
    BMC Infect Dis; 2016 Oct 11; 16(1):556. PubMed ID: 27729016
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ.
    J Microbiol Immunol Infect; 2011 Oct 11; 44(5):364-8. PubMed ID: 21524974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.